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Cardiac sympathetic nervous system (SNS) hyperactivity is a specific hallmark of heart failure (HF)1–6 and represents 
a compensatory response in the initial phase of this syndrome 
aimed at enhancing myocardial inotropism and preserving car-
diac output. However, in the long term, this mechanism promotes 
maladaptive cardiac remodeling, life-threatening ventricular ar-
rhythmias, worsening symptoms, and increased mortality.1–6 In 
the failing heart, a defect of neuronal norepinephrine reuptake 
caused by post-transcriptional downregulation of the cardiac 
norepinephrine transporter7–11 leads to an increase in norepineph-
rine concentration in the sympathetic synapses. This is respon-
sible for impaired myocardial β-adrenergic receptor system and 
functional and anatomic sympathetic denervation of the heart.12,13 
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Rationale: It has been reported that epicardial adipose tissue (EAT) may affect myocardial autonomic function.
Objective: The aim of this study was to explore the relationship between EAT and cardiac sympathetic nerve activity 
in patients with heart failure.
Methods and Results: In 110 patients with systolic heart failure, we evaluated the correlation between echocardiographic 
EAT thickness and cardiac adrenergic nerve activity assessed by 123I-metaiodobenzylguanidine (123I-MIBG). The 
predictive value of EAT thickness on cardiac sympathetic denervation (123I-MIBG early and late heart:mediastinum 
ratio and single-photon emission computed tomography total defect score) was tested in a multivariate analysis. 
Furthermore, catecholamine levels, catecholamine biosynthetic enzymes, and sympathetic nerve fibers were measured 
in EAT and subcutaneous adipose tissue biopsies obtained from patients with heart failure who underwent cardiac 
surgery. EAT thickness correlated with 123I-MIBG early and late heart:mediastinum ratio and single-photon emission 
computed tomography total defect score, but not with left ventricular ejection fraction. Moreover, EAT resulted as 
an independent predictor of 123I-MIBG early and late heart:mediastinum ratio and single-photon emission computed 
tomography total defect score and showed a significant additive predictive value on 123I-MIBG planar and single-
photon emission computed tomography results over demographic and clinical data. Although no differences were 
found in sympathetic innervation between EAT and subcutaneous adipose tissue, EAT showed an enhanced adrenergic 
activity demonstrated by the increased catecholamine levels and expression of catecholamine biosynthetic enzymes.
Conclusions: This study provides the first evidence of a direct correlation between increased EAT thickness 
and cardiac sympathetic denervation in heart failure.  (Circ Res. 2016;118:1244-1253. DOI: 10.1161/CIRCRESAHA. 
115.307765.)
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Furthermore, experimental studies in severe HF animals have 
demonstrated that prolonged exposure of high plasma norepi-
nephrine concentration causes reduced myocardial expression of 
neurotrophic factors such as the nerve growth factor, thus result-
ing in cardiac sympathetic fiber loss.14 Although it is widely rec-
ognized that cardiac SNS hyperactivity in HF is mainly mediated 
by norepinephrine-releasing neurons and by circulating norepi-
nephrine and epinephrine, other mechanisms may contribute to 
SNS hyperactivation. For example, the adipose tissue, particu-
larly the visceral fat depots, may stimulate central SNS activity 
through dysregulated adipokine production and secretion.15–17 
In addition, experimental studies have recently demonstrated 
that adipocytes produce and secrete both norepinephrine and 
epinephrine,18 therefore, suggesting that the sympathetic fibers 
within adipose tissue are not the only source of catecholamines. 
Epicardial adipose tissue (EAT) is the visceral fat depot of the 
heart and represents a source of several adipocytokines and other 
bioactive molecules.19,20 Because of its proximity to the myocar-
dium and absence of fascial boundaries, EAT directly influences 
myocardial homeostasis through vasocrine and paracrine mecha-
nisms. In fact, abnormalities of EAT secretory properties are im-
plicated in the development of pathological conditions, including 
coronary atherosclerosis, left ventricular (LV) hypertrophy, LV 
diastolic dysfunction, and aortic stenosis.20–26 Moreover, EAT 
contains abundant adrenergic and cholinergic nerves that interact 
with the extrinsic nervous system.
The relationship between EAT and cardiac SNS activity 
in HF has not been adequately explored yet. Therefore, in the 
present study, we have investigated the correlation between 
EAT and cardiac adrenergic nerve activity in patients with HF 
caused by LV systolic dysfunction.
Methods
Study Population
The patient population included 110 consecutive patients with HF 
caused by ischemic and nonischemic causes enrolled between January 
2013 and November 2014 at the HF clinic of Federico II University of 
Naples. All patients were clinically referred to cardioverter defibrilla-
tor implantation, as indicated for either primary or secondary preven-
tion. Before cardioverter defibrillator implantation and within 7 days 
from enrollment, patients underwent 123I-metaiodobenzylguanidine 
(123I-MIBG) planar and single-photon emission computed tomogra-
phy (SPECT) imaging and a 2D-echocardiographic study. We used 
the following inclusion criteria: (1) left ventricular ejection frac-
tion (LVEF) ≤50% during optimized medical therapy; (2) stable 
hemodynamic conditions; (3) no acute coronary syndromes in the 
past 6 months. We excluded patients with hemodynamic instability, 
moderate to severe valvular disease, atrial fibrillation or flutter, ven-
tricular paced rhythm, myocardial inflammatory diseases, and subop-
timal echocardiographic image quality. At the time of enrollment, all 
patients underwent a complete clinical examination and blood with-
drawal for routine biochemical determinations. Demographic data 
including age, sex, HF medications, cardiovascular risk factors and 
the presence of comorbidities were also collected. We also included a 
group of 44 healthy subjects matched for age (66.8±12.5), sex (male, 
85%), and body mass index (26.5±1.7). In these control subjects, we 
excluded the presence of cardiovascular diseases, cardiovascular risk 
factors, renal diseases, systemic inflammatory diseases, or any car-
diovascular drug therapy. This group served as a control for echocar-
diographic EAT thickness comparisons. The study was approved by 
the local Ethics Committee. All procedures performed in the study 
were in accordance with the ethical standards of the institutional or 
national research committee and with the 1964 Helsinki declaration 
and its later amendments or comparable ethical standards and con-
formed to the Declaration of Helsinki on human research. All patients 
included in the study gave written informed consent after receiving an 
accurate explanation of the study protocol and of the potential risks 
related to the procedures adopted by the study.
Echocardiographic Study
Echocardiograms were performed by a VIVID E9 (GE Healthcare) 
machine, according to standard techniques. Echocardiographic imag-
es were recorded through an EchoPAC Clinical Workstation Software 
(GE Healthcare).
In all HF patients and in control subjects, measurements of EAT 
thickness were obtained from a parasternal long-axis view. EAT 
thickness was measured at end systole, perpendicularly to the free 
wall of the right ventricle in 3 cardiac cycles as previously described 
by Iacobellis and Willens.27 Measurements of EAT thickness were 
performed offline by 2 independent operators. The average value 
from 3 cardiac cycles was used for the statistical analysis. The intrao-
bserver and interobserver correlation coefficients were tested.
123I-MIBG Myocardial Scintigraphy
All patients with HF underwent planar and SPECT 123I-MIBG car-
diac imaging according to the recommendations of the EANM 
Cardiovascular Committee and the European Council of Nuclear 
Cardiology,28 as previously described in detail.29 We also included 
data from a control group of 10 subjects who underwent cardiac 
123I-MIBG scintigraphy to rule out a disease of the adrenal medulla. 
An activity of 111 MBq 123I-MIBG (Covidien, Mallinckrodt) was in-
travenously administered >1 to 2 minutes after thyroid blockade by 
oral administration of 300 mg of potassium perchlorate. Ten-minute 
planar images of the thorax in standard anterior view (256×256 
matrix) were performed 15 minutes (early image) and 3 hours and 
50 minutes (late image) after tracer administration. Four hours af-
ter tracer administration, a SPECT study (step and shoot mode, 90 
projections, imaging time 30 minutes, 64×64 matrix) was performed. 
Imaging was performed using a dual-head camera system (Skylight, 
Philips) equipped with a low-energy, parallel-hole, high-resolution 
collimator, and the camera peaked at 159 keV with a symmetrical 20% 
energy window. From planar images, the heart:mediastinum (H/M) 
ratio was computed by dividing the mean counts per pixel within the 
myocardium by the mean counts per pixel within the mediastinum. 
Using dedicated postprocessing software on a dedicated workstation 
(Philips), the cardiac region of interest for assessment was polygonal 
in shape and drawn manually over the myocardium including the LV 
cavity on the planar MIBG images. Care was taken to exclude lung 
and liver from the myocardial region of interest. The mediastinal re-
gion of interest with a square shape was placed on the upper half of 
the mediastinum and had a size of 7×7 pixels. The location of the 
mediastinal region of interest was determined using as landmarks the 
lung apex, the upper cardiac border and the medial contours of the 
lungs. H/M ratios were computed for early and late planar imaging 
by dividing the mean counts per pixel within the myocardium by the 
mean counts per pixel within the mediastinum. The MIBG washout 
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H/M heart:mediastinum
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rate was calculated using the following formula: ([early heart counts 
per pixel−early mediastinum counts per pixel]−[late heart counts per 
pixel decay-corrected−late mediastinum counts per pixel decay cor-
rected])/(early heart counts per pixel−early mediastinum counts per 
pixel)×100. SPECT studies were processed with filtered back-projec-
tion and reconstructed into standard long-axis and short-axis images, 
perpendicular to the heart axis. From SPECT images, the defect score 
was calculated by assessing the patient’s segmental tracer uptake 
score using the 17-segment model.30 Each myocardial segment was 
scored according to the following tracer uptake scale: 0 normal, 1 
mildly reduced, 2 moderately reduced, 3 severely reduced, and 4 no 
uptake. The total defect score (TDS) was calculated as the sum of 
the segmental tracer uptake scores (summed score) and separately for 
each vascular territory. Images interpretation was done by consensus 
of 2 independent readers. Intra- and interobserver reproducibility was 
excellent, thus confirming our recent results from a low-dose MIBG 
cardiac imaging protocol in patients with HF.29 No patient was ex-
cluded for poor quality of MIBG images.
Heart Rate Variability Analysis of Cardiac 
Parasympathetic Activity
Heart rate variability (HRV) was assessed from 24-hour ambulatory 
Holter ECG monitoring (Mars System; GE Healthcare). To evaluate 
cardiac parasympathetic activity, we used the root-mean-square of 
the successive normal sinus RR interval difference and the percent-
age of successive normal sinus RR intervals >50 ms (pNN50) in the 
time domain HRV, and the high-frequency oscillation in the spectral 
HRV domain.
Tissues Collection and Norepinephrine and 
Epinephrine Determination
Of 110 patients with HF enrolled into the study, 16 underwent car-
diac surgery for coronary artery bypass grafting. From this group of 
patients, we obtained EAT and subcutaneous adipose tissue (SCAT) 
samples during cardiac intervention. EAT and SCAT biopsy samples 
(average 0.1–0.5 g) were obtained before the initiation of cardiopul-
monary bypass. EAT biopsies were taken near the proximal right cor-
onary artery, whereas SCAT samples were obtained from the chest. 
Tissue sample were homogenized with tissue homogenizer (Ultra-
Turrax, IKA T10) in 1 mL of 0.01 mol/L HCl, 1 mmol/L EDTA, and 
4 mmol/L sodium metabisulfite, stored in ice for 1 hour, and centri-
fuged for 15 minutes (13 100g, 4°C), the supernatants were used for 
the catecholamines determination by enzyme immunoassay.
Norepinephrine and epinephrine were measured in EAT, SCAT, 
and plasma. All measurements were performed using 2-CAT 
Research RIA kits (Labor Diagnostika Nord, Nordhorn, Germany) 
according to the manufacturer’s protocol.
RNA Isolation and Absolute Quantification of 
Tyrosine Hydroxylase, Dopamine-β-Hydroxylase, 
and Phenylethanolamine N-Methyltransferase 
mRNA Levels by Real-Time Polymerase Chain 
Reaction Using SYBR Green
Total RNA was isolated from EAT and SCAT samples with RNasy 
Lipid Tissue Mini Kit (Qiagen) according to the manufacturer’s in-
structions. The purity and concentration of isolated RNA were mea-
sured with NanoDrop (Jenway, Genova Nano). Reverse transcription 
was performed in 20 μL of reaction mixture containing 180 ng of 
total RNA, with High Capacity cDNA Reverse Transcription kits 
(Applied Biosystems) according to the manufacturer’s protocol. 
Absolute mRNA levels of tyrosine hydroxylase (TH), dopamine-β-
hydroxylase (DBH), and phenylethanolamine N-methyltransferase 
(PNMT) were evaluated by quantitative real-time polymerase chain 
reaction on thermocycler iQ5 Multicolor (Bio-Rad). The amounts of 
mRNA were determined by amplification of 18 ng of cDNA target 
using iQ SYBR Green Supermix (Bio-Rad) according to manufac-
turer’s protocols. Reactions also contained 300 nmol each of the 
forward and reverse primers: PNMT forward primer, 59-GCA GCC 
ACT TTG AGG ACA TCA-39; PNMT reverse primer, 59-GGC 
TGT ACA TGC TCC AGT TGA A-39; TH forward primer, 59-
CGG ATG AGG AAA TTG AGA AGC T-39; TH reverse primer, 
59-TCT GCT TAC ACA GCC CGA ACT-59; DBH forward primer 
5′-GTGCTACATTAAGGAGCTTCCAAAG-3′), reverse primer 
5′-GGCCTCATTGCCCTTGGT-3′. GAPDH rRNA was used as en-
dogenous control.
Real-time polymerase chain reaction conditions were a typical 
2-step real-time polymerase chain reaction protocol, 2 minutes at 
95°C, followed by 40 cycles of denaturation for 15 seconds at 95°C 
and annealing/extension for 30 seconds at 60°C. The polymerase 
chain reaction products were quantified with an automatic sequence 
detection system at each step of amplification using the Optical 
System Software (version 2.1; Bio-Rad).
Immunoblotting
SCAT and EAT samples were weighed (≈15 mg) and lysed in 150 
μL of RIPA buffer with protease and phosphatase inhibitors cocktail 
(Roche). Protein concentrations in all lysates were measured using 
a dye-binding protein assay kit (Bio-Rad) and a spectrophotom-
eter reader (Bio-Rad) at a wavelength of 750 nm. Protein levels of 
TH were detected by protein immunoblotting using a 1:1000 anti-
rabbit IgG (Millipore AB152); PNMT was detected using 1:1000 
anti-mouse IgG (WH0005409M6; Sigma); GAPDH was used as 
internal loading control. Secondary antibodies were purchased 
from ImmunoReagents, Inc., Raleigh. Bands were visualized by 
enhanced chemiluminescence (ECL; Millipore Immobilon, Western 
Chemiluminescent HRP Substrate) and were quantified using densi-
tometry (Chemidoc; Bio-Rad).
Immunohistochemical Procedures
EAT and SCAT samples were frozen at −80°C and cut in 50-μm con-
secutive thick sections using a freezing microtome (Leica 2000R, 
Germany). Free-floating sections were processed by means of indi-
rect immunofluorescence technique using rabbit polyclonal antibod-
ies against TH (Millipore AB152, 1:1000) to mark sympathetic nerve 
fibers. In both EAT and SCAT, most of the sympathetic nerve fibers 
were localized along vessels with few scattered fibers randomly dis-
tributed. Therefore, to quantify vascular innervation, digital images of 
all vessels found in 42 stained sections were acquired using nonlaser 
confocal microscopy (Apotome confocal system; Zeiss, Oberkochen, 
Germany). The highest number of fibers running along the vessel and 
intercepting a superimposed line perpendicular to the major axis of 
the vascular structure were counted. We measured the total number 
of intercepts for each vessel and the nerve density calculated as the 
mean number of intercepts per vessel caliber in μm (fibers/μm). A 
single operator blindly performed all the measurements.
Statistical Analysis
Continuous variables were expressed as mean±SD and compared by the 
use of Student t test (normally distributed) or as median±interquartile 
range value and compared by the use of Mann–Whitney U test (not 
normally distributed), as appropriate. Normality of data distribution 
was evaluated using the Kolmogorov–Smirnov test. Categorical vari-
ables were expressed as proportion and compared by use of χ2 test. 
Pearson correlation coefficient was calculated to assess correlation 
between data. To determine the independent predictors of 123I-MIBG 
early and late H/M, and late SPECT, variables achieving P<0.10 on 
univariate analysis (age, sex, LVEF, New York Heart Association 
[NYHA] class, body mass index, ischemic versus non ischemic HF 
cause, diabetes mellitus, hypertension, dyslipidemia, and EAT thick-
ness) were then included in a multivariate linear regression analysis. 
The additive predictive value of EAT thickness on 123I-MIBG planar 
and SPECT results was assessed by the increase of r2 in a 3-step linear 
regression modeling. The first step consisted of fitting a multivariate 
model 1 of age, sex, NYHA class, HF of ischemic cause, diabetes mel-
litus, hypertension, and dyslipidemia. Then, LVEF was included in the 
second step. Next, EAT thickness was included in the third step. The 
change in overall r2 was used to assess the increase in predictive power 
after the addition of each variable. All data were collected in an Excel 
database and analyzed by SPSS version 19.0 (SPSS, Inc., Chicago, 
IL). Statistical significance was accepted at P<0.05.
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Results
Patient Characteristics
Table 1 illustrates demographic, clinical, echocardiographic, 
and 123I-MIBG characteristics of the HF population. The mean 
age was 64.74±10.50 years and 85.5% of patients were men. 
The majority of the patients were in NYHA class II (60%) and 
III (36.4%). Ischemic cause of HF was recognized in 72% of 
cases. Forty-two percent of the patients were diabetics, 74% 
had hypertension, 45% were smokers, and 72% had dyslipid-
emia. The majority of the patients were on optimal HF drug 
therapy. Mean LVEF was 38.1±9.3%, and mean EAT thick-
ness was 8.6±2.55 mm. At 123I-MIBG scintigraphy, mean early 
and late H/M were significantly lower than in healthy controls 
(early H/M, 1.76±0.23 versus 2.23±0.18; P<0.0001; late H/M, 
1.57±0.25 versus 2.14±0.19; P<0.0001; Online Figure I). In 
the patients with HF, the washout rate was 10.83±10.04, and 
the mean SPECT TDS was 35.6±16.8. Overall, these data are 
consistent with cut-off data previously reported by our group 
and others10,11 and indicate a significant cardiac sympathetic 
denervation. In patients with HF, the EAT thickness value was 
significantly higher than in controls (8.6±2.55 versus 4.7±1.24 
mm; P<0.001), which is consistent with the increase in LV 
end-diastolic mass (202±48 versus 122±26 g; P<0.01).24 
The reproducibility for echocardiographic EAT thickness as-
sessment was excellent (intraobserver, 0.897; interobserver, 
0.921).
Correlation Between Echocardiographic 
EAT Thickness and Cardiac 123I-MIBG Data: 
Multivariable Predictors of Cardiac Sympathetic 
Denervation
EAT thickness showed a weak, although significant, correla-
tion with planar 123I-MIBG parameters (early and late H/M), 
whereas a more evident correlation was found with 123I-MIBG 
SPECT TDS (Figure 1; Online Table I). There was no correla-
tion between EAT and LVEF (Online Table I). Noteworthy, 
LVEF significantly correlated with late H/M (r = 0.388; 
P<0.0001), but not with early H/M, washout rate and SPECT 
TDS (Online Table II).
Multivariate linear regression analyses were used to as-
sess the predictors of 123I-MIBG planar and SPECT param-
eters (Table 2). The EAT thickness resulted as a significant 
independent predictor of 123I-MIBG early and late H/M, and 
SPECT TDS. LVEF and NYHA class significantly predicted 
both early and late H/M, but not SPECT TDS. The incremen-
tal predictive value of EAT thickness on 123I-MIBG planar and 
SPECT parameters was evaluated from the increase of r2 in a 
3-step linear regression modeling (Figure 2). For 123I-MIBG 
SPECT TDS (Figure 2A), early (Figure 2B), and late H/M 
(Figure 2C), the addition of EAT thickness significantly in-
creased global r2 (P<0.05) over model 1 (including age, sex, 
body mass index, NYHA class, HF of ischemic cause, diabe-
tes mellitus, hypertension, and dyslipidemia) plus LVEF.
EAT Thickness, Cardiac Sympathetic Denervation, 
and LV Mass
LV mass significantly correlated with both EAT thickness and 
cardiac sympathetic denervation expressed by 123I-MIBG late 
H/M (Figure 3). The significant correlation between EAT and 
123I-MIBG late H/M is illustrated in Figure 1.
Catecholamine Concentration, Catecholamine 
Biosynthetic Enzymes, and Sympathetic 
Innervation in EAT and SCAT
EAT and SCAT from patients with HF contained both nor-
epinephrine and epinephrine. More important, EAT showed 
a 5.6-fold increase of norepinephrine levels when com-
pared with SCAT (0.168±0.026 versus 0.030±0.008 ng/
Table 1. Demographic and Clinical Characteristics of the 
Study HF Population
All (n=110)
Age, y 64.74±10.50
Sex, male, % (n) 85.5 (94)
BMI, kg/m2 28.6±4.4
NYHA class, % (n)
  I 3.6 (4)
  II 60 (66)
  III 36.4 (40)
HF ischemic cause, % (n) 71.8 (79)
Family history of CAD, % (n) 24.5 (27)
Diabetes mellitus, % (n) 41.8 (46)
Hypertension, % (n) 74.5 (82)
Smokers, % (n) 45.5 (50)
Dyslipidemia, % (n) 71.8 (79)
CKD, % (n) 15.5 (17)
COPD, % (n) 32.7 (36)
Cardiac drug therapy, % (n)
  ACE-I/ARBs 80.9 (89)
  MRA antagonist 43.6 (48)
  CCBs 10.0 (11)
  BBs 75.5 (83)
Echocardiographic data
  EAT thickness, mm 8.6±2.55
  LVEF, % 38.1±9.3
  LV-EDM, g 202±48
123I-MIBG myocardial scintigraphy
  Early H/M 1.76±0.23
  Late H/M 1.57±0.25
  Washout rate 10.83±10.04
  SPECT TDS 35.6±16.8
ACE-I indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin 
receptor blockers; BB, β-blockers; BMI, body mass index; CAD, coronary 
artery disease; CCB, calcium channel blockers; CKD, chronic kidney disease; 
COPD, chronic obstructive pulmonary disease; EAT, epicardial adipose tissue; 
H/M, heart:mediastinum ratio; HF, heart failure; 123I-MIBG, iodine-123 meta-
iodobenzylguanidine; LV-EDM, left ventricular end-diastolic mass; LVEF, left 
ventricular ejection fraction; MRA, mineralcorticoid antagonists; NYHA, New 
York Heart Association; SPECT, single-photon emission computed tomography; 
and TDS, total defect score.
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mL; P<0.0001) and a 2-fold increase when compared with 
plasma (0.168±0.026 versus 0.085±0.014 ng/mL; P=0.017; 
Figure 4A). Epinephrine levels were significantly higher in 
EAT than in SCAT (0.016±0.001 versus 0.008±0.0005 ng/
mL; P<0.0001), but lower than in plasma (0.016±0.001 versus 
0.06±0.008 ng/mL; P<0.0001; Figure 4A).
We investigated whether norepinephrine and epineph-
rine were produced in adipose tissues. Gene expression of 
all catecholamine biosynthetic enzymes (TH, DBH, and 
PNMT) was evident in both EAT and SCAT. mRNA levels of 
norepinephrine-synthesizing enzymes (TH and DBH) were 
significantly higher in EAT than in SCAT (8.6-fold and 6.5-
fold increase, respectively), which explained the higher nor-
epinephrine concentrations in EAT (Figure 4B). We observed 
a robust increase of both TH and PNMT protein levels in EAT 
when compared with protein levels in SCAT (Figure 4C). The 
increased protein expression of PNMT in EAT when com-
pared with SCAT was not paralleled by a similar (statistically 
significant) increase at the mRNA level. We quantified sym-
pathetic nerve fibers in a total number of 45 vessels. We did 
not find differences in the mean number of fibers per vessel 
between EAT and SCAT (Figure 4D). On the contrary, the 
mean vessel diameter in EAT was significantly higher than 
SCAT vessel diameter (100.37±53.35 and 58.76±30.64 μm, 
respectively; P<0.001). Therefore, the fiber density per ves-
sel diameter was significantly higher in SCAT than in EAT 
(P<0.001; Figure 4D). Taken together, these data indicate 
a higher SNS activation in EAT than in SCAT in our HF 
population.
EAT and Cardiac Parasympathetic Activity
HRV data of cardiac parasympathetic activity in patients with 
HF are reported in Online Table III.
Because our evidence indicated a correlation between 
EAT thickness and cardiac sympathetic nerve derangement, 
we also explored the relationship between EAT thickness 
and HRV measures of cardiac parasympathetic activity. In 
our HF population, EAT thickness did not correlate with 
pNN50 (Pearson = 0.102; P=0.67), root-mean-square of the 
successive normal sinus RR interval difference (Pearson = 
0.079; P=0.74), and high-frequency oscillation (Pearson= 
0.051; P=0.83; Online Table IV).
Figure 1. Correlation between epicardial adipose tissue (EAT) thickness and planar (early and late heart:mediastinum ratio 
[H/M]; washout rate) and single-photon emission computed tomography (SPECT) data at cardiac 123I-metaiodobenzylguanidine 
(123I-MIBG) imaging.
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Discussion
The findings of the present study, obtained in patients with 
systolic HF, demonstrate that a highly significant correlation 
exists between EAT thickness and cardiac sympathetic de-
nervation assessed by cardiac 123I-MIBG; furthermore, EAT 
thickness predicts cardiac 123I-MIBG planar and SPECT pa-
rameters, incrementally to clinical and LV function data. 
Finally, EAT represents an important source of catechol-
amines in patients with HF.
EAT and Cardiac Sympathetic Denervation
EAT represents the visceral fat depot of the heart which cov-
ers 80% of the heart’s surface and constitutes 20% of its to-
tal weight.20 It is known that in pathological conditions, EAT 
may play an unfavorable activity for the heart through pro-
duction and secretion of proinflammatory and proatherogenic 
factors.19–21 Importantly, recent studies have also indicated a 
close relationship between EAT and myocardial autonomic 
function.31,32 Many EAT-derived factors can directly modulate 
the electrophysiological properties and ion currents of myo-
cytes and may promote arrhythmogenesis.33 Moreover, EAT 
contains both adrenergic and cholinergic nerves which inter-
act with the extrinsic SNS and para-SNS.34,35 Simultaneous 
activation of these nerve structures within EAT in response to 
extrinsic nerve activation may enhance triggered activity and 
facilitate the development of cardiac arrhythmias.32 In this 
study, we have demonstrated that EAT represents an impor-
tant source of norepinephrine, whose levels are 2-fold higher 
than those found in plasma. Because of the EAT proximity 
to the myocardium, the increase in catecholamine content 
in this tissue could result in a negative feedback on cardiac 
sympathetic nerves, which are associated with the ventricular 
myocardium, thus inducing a functional and anatomic dener-
vation of the heart. This hypothesis is supported by our find-
ings showing a direct correlation between EAT thickness and 
the degree of cardiac sympathetic denervation assessed by 
cardiac 123I-MIBG. Therefore, in the context of a widespread 
SNS hyperactivity in HF, EAT seems to play an additive role 
in generating the final net effect of cardiac sympathetic dener-
vation. In fact, when the failing myocardium shows depletion 
of norepinephrine stores because of reduced mechanisms of 
norepinephrine uptake,7 circulating catecholamines derived 
from peripheral organs might play a prominent role in per-
petuating the progression of cardiac sympathetic denervation. 
This is particularly relevant given the importance of cardiac 
sympathetic nerves in cardiac homeostasis36 and repair.37 In 
this regard, it has been demonstrated that cardiac chemical 
sympathectomy in rats induces LV contractility dysfunction, 
increased circulating levels of markers of severe myocardial 
damage, and cardiac inflammatory reactions.36 In addition, 
sympathetic denervation completely blocks cardiac regenera-
tive responses after injury in neonatal hearts.37
In our analysis, the EAT thickness was an independent 
predictor of 123I-MIBG planar and SPECT parameters and pro-
vided additional predictive information on cardiac adrenergic 
nerve activity respect to important demographic, clinical, and 
LV function parameters. Therefore, assessing EAT thickness 
in patients with HF may provide surrogate information on the 
status of cardiac adrenergic derangement, independently from 
the degree of LV systolic dysfunction and clinical variables. 
On the contrary, the increase in SNS activity in the EAT did 
not show any effect on cardiac parasympathetic activity. In 
this regard, the interaction between cardiac sympathetic and 
parasympathetic innervation and its effect on cardiac para-
sympathetic activity has been largely unexplored. The evi-
dence comes only from few experimental studies conducted 
Table 2. Multivariable Predictors of 123I-MIBG Planar and 
SPECT Data
β
Lower  
95% CI
Upper  
95% CI
P 
Value
123I-MIBG early H/M
  Age −0.001 −0.006 0.004 0.568
  Sex −0.083 −0.226 0.059 0.269
  BMI −0.012 −0.025 0.0002 0.159
  NYHA −0.119 −0.202 −0.035 0.006
  HF ischemic cause 0.009 −0.056 0.076 0.768
  Diabetes mellitus 0.018 −0.066 0.104 0.688
  Hypertension 0.084 −0.032 0.202 0.236
  Dyslipidemia −0.039 −0.153 0.074 0.594
  LVEF 0.005 0.0006 0.011 0.002
  EAT thickness −0.030 −0.048 −0.012 0.001
123I-MIBG late H/M
  Age −0.005 −0.010 0.0002 0.053
  Sex −0.073 −0.217 0.071 0.398
  BMI −0.004 −0.017 0.009 0.522
  NYHA −0.162 −0.248 −0.075 0.000
  HF ischemic cause 0.029 −0.037 0.096 0.353
  Diabetes mellitus −0.031 −0.117 0.055 0.431
  Hypertension 0.128 0.010 0.247 0.082
  Dyslipidemia −0.010 −0.125 0.104 0.858
  LVEF 0.007 0.002 0.012 0.009
  EAT thickness −0.034 −0.052 −0.014 0.001
123I-MIBG SPECT TDS
  Age, y 0.130 −0.281 0.542 0.592
  Sex −6.342 −17.779 5.095 0.402
  BMI −0.420 −1.456 0.615 0.434
  NYHA 1.719 −4.661 8.100 0.341
  HF ischemic cause 4.340 −3.042 11.723 0.580
  Diabetes mellitus 1.503 −5.022 8.029 0.645
  Hypertension 3.455 −5.122 12.033 0.465
  Dyslipidemia 4.850 −4.552 14.252 0.412
  LVEF −0.452 −0.877 −0.027 0.072
  EAT thickness 4.392 3.169 5.614 0.000
BMI indicates body mass index; CI, confidence interval; EAT, epicardial 
adipose tissue; H/M, heart:mediastinum ratio; HF, heart failure; 123I-MIBG, 
iodine-123 meta-iodobenzylguanidine; LVEF, left ventricular ejection fraction; 
NYHA, New York Heart Association; and TDS, total defect score.
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in non-HF animal models,36 thus avoiding comparisons with 
our results obtained in the clinical setting.
Overall, these findings seem particularly relevant given 
the well-recognized importance to assess cardiac sympathetic 
denervation for the prognostic stratification of patients with 
advanced HF.11
In our patients with HF, the EAT thickness value was sig-
nificantly higher than in controls consistent with the increase 
in LV end-diastolic mass.24,38 Interestingly, according to pre-
vious evidence reporting a relationship between LV hyper-
trophy and cardiac sympathetic denervation in hypertensive 
patients,39 our data indicate a close relationship between EAT, 
Figure 2. Additive predictive value of 
epicardial adipose tissue (EAT) thickness on 
123I-metaiodobenzylguanidine single-photon 
emission computed tomography total defect 
score (TDS) (A) and planar (early [B] and late 
[C] heart:mediastinum ratio [H/M], assessed by 
the increase of r 2 in a 3-step linear regression 
modeling. The first step consisted of fitting a 
multivariate model 1 of age, gender, body mass 
index, New York Heart Association class, heart 
failure of ischemic cause, diabetes, hypertension 
and dyslipidemia. Left ventricular ejection fraction 
(LVEF) was included in the second step (model 
1+LVEF). EAT thickness was included in the third 
step. The change in overall r2 was used to assess 
the increase in predictive power after the addition 
of each variable.
Figure 3. A, Correlation between epicardial adipose tissue (EAT) thickness and indexed left ventricular (LV) mass. B, Correlation 
between 123I-metaiodobenzylguanidine (123I-MIBG) late heart:mediastinum (H/M) ratio and indexed LV mass.
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cardiac sympathetic denervation, and HF severity expressed 
by the increase of LV mass.
Catecholamine Production in EAT
Adipose tissues contain a rich sympathetic innervation.40–42 
Activation of fat sympathetic fibers leads to the release of 
catecholamines (mainly norepinephrine), which stimulate fat 
cell β1, β2, β3, and α2-adrenergic receptors; this mechanism 
activates or inhibits the lipolysis process.42–46 Catecholamines 
are considered the major regulators of lipolysis45,46 and also 
affect differentiation and proliferation of adipocytes.47,48 
Catecholamine biosynthesis is catalyzed primarily by TH, 
DBH, and PNMT enzymes,49 and recent studies have indicated 
that the genes of these enzymes are differentially expressed in 
various adipose tissue depots.18 The present study reports the 
first evidence of SNS activation in EAT of patients with HF. 
In fact, norepinephrine and epinephrine were both present in 
EAT; moreover, norepinephrine concentrations were higher 
than in SCAT and plasma. Accordingly, catecholamine signal 
transduction pathways were also found in EAT with a signifi-
cant expression of genes (mRNA of TH, DBH, and PNMT) 
involved in the synthesis of norepinephrine and epinephrine. 
Notably, catecholamine levels and expression of the enzymes 
Figure 4. A, Norepinephrine and epinephrine determination by enzyme immunoassay in epicardial adipose tissue (EAT), subcutaneous 
adipose tissue (SCAT), and plasma of patients with heart failure. B, Quantification of tyrosine hydroxylase (TH), dopamine-β-hydroxylase 
(DBH), and phenylethanolamine N-methyltransferase (PNMT) mRNA levels by real-time polymerase chain reaction in SCAT and EAT. C, 
Average densitometric quantitative analysis (left) and representative Western blot (right) from blots showing the ratio of TH and PNMT to 
GAPDH in SCAT and EAT. D, Sympathetic nerve fibers density in SCAT and EAT expressed as number of fibers per vessel and fiber per 
micrometer of vessel diameter (left) and representative confocal images (right) showing sympathetic nerve fibers along vessels in SCAT 
and EAT obtained from a patient with heart failure. Fibers are marked with TH antibodies. Scale bar, 50 μm in SCAT and 100 μm in EAT.
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involved in catecholamine biosynthesis were significantly 
higher in EAT than in SCAT. However, based on the histologi-
cal analysis, SNS hyperactivity found in EAT was not associ-
ated with EAT hyperinnervation. These findings may explain, 
at least in part, the strong correlation between EAT thickness 
and 123I-MIBG parameters observed in patients with HF. This 
supports the hypothesis that increased EAT directly contributes 
to SNS hyperactivity in the heart that accompanies and fosters 
myocardial sympathetic denervation and disease progression.
Limitations
The current study reports a single-center experience in a rela-
tively small group of patients, and a mid-/long-term follow-up 
was not available for our study population.
Echocardiographic EAT measurement has several advan-
tages, such as low cost and easy availability, but it also has 
some limitations because it might not fully reflect the variabil-
ity of fat thickness or total EAT volume. However, the EAT 
echocardiographic evaluation has been reported to correlate 
with magnetic resonance measurements27 and has an excellent 
reproducibility,50 as confirmed in the current study.
The lack of a control group of patients without HF under-
going EAT and SCAT catecholamine measurements represents 
a limitation of the study. Another question could be raised on 
the influence of circulating catecholamines on the levels of 
norepinephrine and epinephrine in EAT and SCAT. However, 
norepinephrine levels in EAT were higher than in plasma, thus 
indicating a local production. Finally, the presence of genes of 
the catecholamine biosynthetic enzymes found in both EAT 
and SCAT points to an endogenous production of catechol-
amines in these adipose tissues.
Conclusions
In patients with HF, EAT independently correlates with cardiac 
sympathetic denervation and represents a source of catechol-
amine production. SNS activation in EAT might contribute to 
cardiac sympathetic denervation and disease progression in 
HF. These results pave the way for future evaluation on the 
potential use of EAT thickness as an index of cardiac adrener-
gic nerve activity and prognosis in patients with HF.
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What Is Known?
•	 Epicardial adipose tissue (EAT) has a close relationship with myocar-
dial autonomic function, directly modulates cardiac electrophysiologi-
cal properties, and may promote arrhythmogenesis in pathological 
conditions.
What New Information Does This Article Contribute?
•	 In patients with heart failure (HF), EAT represents a relevant source 
of catecholamines, which could contribute to anatomic and functional 
sympathetic denervation of the failing myocardium.
EAT represents the visceral fat depot of the heart and influences 
myocardial homeostasis through vasocrine and paracrine mecha-
nisms. EAT contains abundant adrenergic nerves that interact with 
the extrinsic nervous system to modulate the cardiac autonomic sys-
tem. This study explores for the first time the relationship between 
EAT and cardiac sympathetic denervation in patients with HF. In 
110 patients with systolic HF, we observed a significant correlation 
between increased echocardiographic EAT thickness and cardiac 
sympathetic denervation assessed by 123I-metaiodobenzylguanidine 
myocardial scintigraphy. Furthermore, we found increased levels of 
catecholamines and catecholamine biosynthetic enzymes within 
EAT. This represents the first demonstration of a sympathetic ner-
vous system hyperactivity in the cardiac visceral fat of HF patients. 
Because of the proximity to the myocardium and the high catechol-
amine content, EAT could induce a negative feedback on cardiac 
sympathetic nerves, therefore contributing to functional and ana-
tomic denervation of the failing heart. This is particularly relevant 
given the importance of cardiac sympathetic denervation on cardiac 
homeostasis and repair. Our results pave the way for future evalu-
ation on the potential use of EAT thickness as an index of cardiac 
adrenergic nerve activity and prognosis in HF patients.
Novelty and Significance
 by guest on April 26, 2016http://circres.ahajournals.org/Downloaded from 
Dario Leosco
Antonio De Bellis, Enrico Coscioni, Teresa Pellegrino, Alberto Cuocolo, Nicola Ferrara and 
Gabriella Grimaldi, Francesco Baldascino, Maria Nolano, Andrea Elia, Alessandro Cannavo,
Femminella, Stefania Paolillo, Laura Petraglia, Giuseppina Gambino, Aurelio Caruso, Maria 
Valentina Parisi, Giuseppe Rengo, Pasquale Perrone-Filardi, Gennaro Pagano, Grazia Daniela
Denervation in Patients With Heart Failure
Increased Epicardial Adipose Tissue Volume Correlates With Cardiac Sympathetic
Print ISSN: 0009-7330. Online ISSN: 1524-4571 
Copyright © 2016 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231Circulation Research 
doi: 10.1161/CIRCRESAHA.115.307765
2016;118:1244-1253; originally published online February 29, 2016;Circ Res. 
 http://circres.ahajournals.org/content/118/8/1244
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 http://circres.ahajournals.org/content/suppl/2016/02/29/CIRCRESAHA.115.307765.DC1.html
Data Supplement (unedited) at:
  
 http://circres.ahajournals.org//subscriptions/
is online at: Circulation Research  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer about this process is available in the
located, click Request Permissions in the middle column of the Web page under Services. Further information
Editorial Office. Once the online version of the published article for which permission is being requested is 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not theCirculation Researchin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 by guest on April 26, 2016http://circres.ahajournals.org/Downloaded from 
 SUPPLEMENTAL MATERIALS 
 
Online Table I. Correlation between echocardiographic EAT thickness, and cardiac 
123
I-MIBG planar 
and SPECT data, and LVEF. 
 
                                   EAT 
  Pearson p value 
 
123
I-MIBG planar and SPECT data 
     
      Early H/M -0.305 .001 
 
      Late H/M -0.332 .0001 
 
      Wash-out rate .121 .210 
 
      SPECT TDS 0.701 .0001 
 
LVEF -.122 .272 
 
    
EAT, epicardial adipose tissue; 
123
I-MIBG, iodine-123 meta-iodobenzylguanidine; H/M, heart to 
mediastinum ratio; TDS, total defect score; LVEF, left ventricular ejection fraction. 
 
 
 
 
 
 
Online Table II. Correlation between LVEF and cardiac 
123
I-MIBG planar and SPECT data. 
 
                                    
                        LVEF 
  Pearson p value 
 
123
I-MIBG planar and SPECT data 
     
      Early H/M 0.179   .106 
 
      Late H/M 0.388  <.0001 
 
      Wash-out rate  -0.146  .187 
 
      SPECT TDS  -0.263  .051 
 
    
LVEF, left ventricular ejection fraction; 
123
I-MIBG, iodine-123 meta-iodobenzylguanidine; H/M, heart to 
mediastinum ratio; TDS, total defect score. 
  
Online Table III. Heart rate variability data on cardiac parasympathetic activity in HF patients 
      pNN50, % 13.05±17.23 
40.08±27.40 
218.96±272.48 
      rMMSD, msec 
      HF, msec
2
 
pNN50, percentage of successive normal sinus RR intervals >50 ms;  rMSSD, root-mean-square of the 
successive normal sinus RR interval difference;  HF, high frequency oscillation  
    
    
 
 
 
   
Online Table IV. Correlation between EAT and cardiac parasympathetic activity assessed by HRV 
  
                     EAT 
 
Pearson 
 
 
p value 
 
HRV parameters 
     
      pNN50 0.102   .678 
 
      rMMSD 0.079  .747 
 
      HF 0.051  .083 
 
EAT, epicardial adipose tissue; HRV, heart rate variability; pNN50, percentage of successive normal sinus 
RR intervals >50 ms;  rMSSD, root-mean-square of the successive normal sinus RR interval difference;  HF, 
high frequency oscillation  
 
 
 
 
 
  
  
